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1  | INTRODUC TION
Aging is associated with a time-dependent functional decline 
induced by the interaction of several mechanisms (Lopez-Otin, 
Blasco, Partridge, Serrano, & Kroemer, 2013). This process in-
creases the susceptibility to various degenerative pathological 
conditions, leading to high morbidity rates and, eventually, death 
(Campisi, Andersen, Kapahi, & Melov, 2011). Indeed, the inci-
dence of many diseases, such as atherosclerosis, osteoporosis, 
arthritis, hypertension, Alzheimer's and cancer, increases with 
age (Munoz-Espin & Serrano, 2014). This link between aging 
and debilitating ailments has fuelled the search for anti-aging 
interventions.
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Abstract
One of the hallmarks of aging is the progressive accumulation of senescent cells in 
organisms, which has been proposed to be a contributing factor to age-dependent 
organ dysfunction. We recently reported that Bruton's tyrosine kinase (BTK) is an 
upstream component of the p53 responses to DNA damage. BTK binds to and phos-
phorylates p53 and MDM2, which results in increased p53 activity. Consistent with 
this, blocking BTK impairs p53-induced senescence. This suggests that sustained 
BTK inhibition could have an effect on organismal aging by reducing the presence of 
senescent cells in tissues. Here, we show that ibrutinib, a clinically approved covalent 
inhibitor of BTK, prolonged the maximum lifespan of a Zmpste24−/− progeroid mice, 
which also showed a reduction in general age-related fitness loss. Importantly, we 
found that certain brain functions were preserved, as seen by reduced anxiety-like 
behaviour and better long-term spatial memory. This was concomitant to a decrease 
in the expression of specific markers of senescence in the brain, which confirms a 
lower accumulation of senescent cells after BTK inhibition. Our data show that block-
ing BTK has a modest increase in lifespan in Zmpste24−/− mice and protects them from 
a decline in brain performance. This suggests that specific inhibitors could be used in 
humans to treat progeroid syndromes and prevent the age-related degeneration of 
organs such as the brain.
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Although not all the causal events have been fully characterized, 
it has been proposed that the main determining factors of aging 
can be summarized into nine groups: genomic instability, telomere 
attrition and telomere damage, epigenetic alterations, loss of pro-
teostasis, deregulated nutrient sensing, mitochondrial dysfunction, 
accumulation of senescent cells, stem cell exhaustion and altered 
intercellular communication, collectively known as the hallmarks 
of aging (Lopez-Otin et al., 2013). Efforts to slow down age-related 
dysfunctions are currently being aimed at preventing one or more of 
these events.
Of all these hallmarks, senescent cells have been recently gaining 
prominence as a promising anti-aging target. Senescent cells disrupt 
tissue homeostasis by secreting factors that promote inflammation, 
tumour growth and tissue damage, and this leads to a functional de-
cline and age-related symptoms (Tchkonia, Zhu, Deursen, Campisi, & 
Kirkland, 2013). Moreover, senescent cells are a contributing factor 
in the development of pulmonary fibrosis, bronchiectasis, osteo-
arthritis, anxiety, liver steatosis and atherosclerosis, among other 
chronic diseases (Munoz-Espin & Serrano, 2014). Recent evidence 
has shown that eliminating senescent cells leads to prolonged lifes-
pan and time lived in full health (healthspan) in mammalian models 
(Baker et al., 2016, 2011; Xu et al., 2018), thus confirming that the in-
creased presence of senescent cells in tissues has an important role 
in aging phenotypes. This provides a rationale for devising therapeu-
tic strategies to prevent a time-dependent buildup of senescent cells 
in human tissues, which could potentially ameliorate the symptoms 
of aging as well as prevent age-related pathologies.
In order to devise novel strategies to detect senescent cells, we 
performed a screening of the senescent surfaceome, those pro-
teins present in or associated with the plasma membrane of senes-
cent cells (Althubiti et al., 2014). We identified several new specific 
markers, including the Bruton's tyrosine kinase (BTK), a nonreceptor 
tyrosine kinase that belongs to the Tec family and is essential for 
B-cell maturation (Mohamed et al., 2009). BTK is located at the cell 
membrane but it can also be found in the nucleus, and it has been 
shown to have pro-apoptotic and tumour suppressor functions (Ta 
et al., 2010). In B cells, BTK is activated after an antigen binds to the 
B-cell receptor, which leads to its phosphorylation at tyrosine 551 
by SRC family kinases and its autophosphorylation at tyrosine 223 
(Rawlings et al., 1996). A pathological BTK upregulation has been 
shown in B-cell malignancies such as chronic lymphocytic leukaemia 
(Herman et al., 2011).
We have reported that BTK is a crucial part of the p53 pathway, 
where it acts as a modulator of p53 activity (Althubiti et al., 2016). 
We found that BTK is expressed in response to damage and induces 
phosphorylation of the N-terminus of p53, which leads to increases 
in protein levels and activity. Also, BTK binds to and phosphorylates 
MDM2, mediating a loss of ubiquitination activity and further stabi-
lizing p53 (Rada et al., 2017). BTK has a similar effect on p73, a p53 
family member that also acts as a tumour suppressor (Rada, Barlev, & 
Macip, 2018a). Inhibition of BTK interferes with the upregulation of 
p53 target genes, which lead to a severe impairment in the induction 
of p53-mediated cell fates, especially senescence (Althubiti et al., 
2016). This defines a novel role of BTK in tumour suppression (Rada, 
Barlev, & Macip, 2018b).
Given this important regulatory role of BTK in p53-induced se-
nescence, we reasoned that blocking BTK activity for prolonged 
periods of time could prevent the accumulation of senescent cells 
in vivo and thus diminish some of the deleterious effects of aging. 
Here, we show that chemical inhibitors of BTK can indeed increase 
lifespan and healthspan in animal models of premature aging. Of 
particular interest is the preservation of certain cognitive functions 
in mice when BTK is chronically inhibited. We propose that BTK 
inhibitors could be a clinically relevant strategy to protect humans 
from age-related loss of fitness, especially when a cognitive decline 
is anticipated.
2  | RESULTS
2.1 | BTK inhibition reduces the impact of aging in 
progeroid mice
We have previously shown that blocking BTK hampers p53-induced 
senescence in vitro (Althubiti et al., 2016). We reasoned that BTK in-
hibition could thus prevent accumulation of senescent cells in vivo. 
According to recent reports (Baker et al., 2016, 2011), this could 
lead to an amelioration of age-related conditions and an increased 
lifespan. To test this possibility, we used ibrutinib (PCI-32765), an 
inhibitor that irreversibly binds to the C481 residue of BTK and in-
hibits Y223 stimulation and has been approved to treat mantle cell 
lymphoma and CLL (Aalipour & Advani, 2014). We studied its ef-
fects on Zmpste24−/− mice, which display a premature aging pheno-
type with an average maximum lifespan of 8 months (Pendas et al., 
2002), mediated at least in part by a pathological increase in p53 
signalling (Varela et al., 2005). Mice were dosed with 10 mg/kg ibru-
tinib continuously (twice a week by oral gavage) from 2 months of 
age up to 8 months (or when the humane end points were reached, 
as described in Table S1). As hypothesized, this leads to a reduction 
in the accumulation of senescent cells in different tissues, as meas-
ured by the expression of several senescent markers by Western 
blot and qPCR (Figure S1a,b). Although we did not observe any 
changes in the average lifespan of treated mice when compared 
to controls (Figure 1a), the maximum survival was increased (from 
202 to 230 days). This was accompanied by a statistically signifi-
cant difference in survival in the longest lived mice (boxed area). 
When these mice were analysed for signs associated with frailty 
(Whitehead et al., 2014; Table S2), we observed that there were no 
differences in the first 4 months after initiating treatment, during 
which the scores were low for both control and treatment groups 
(Figure 1b). However, health started to deteriorate in the control 
mice after that point, whereas it was preserved in the treated ani-
mals (Figure 1b,c). Of note, none of the treated animals had impor-
tant side effects (see Table S2). There were no visible tumours in 
these mice, which could have resulted from the inhibition of tu-
mour suppressors such as p53, and no cancers were observed in 
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necropsies (data not shown). These results show that a prolonged 
ibrutinib treatment can ameliorate aging in progeroid mice by mod-
estly increasing lifespan, generally reducing frailty and significantly 
extending their maximum lifespan.
2.2 | Expression of BTK in brains of aged mice
Given the fact that BTK expression is unlikely to be homogenous in 
all aged tissues, we hypothesized that the effects of BTK inhibition 
F I G U R E  1   Ibrutinib effects on lifespan and healthspan of progeroid mice. (a) Kaplan–Meier survival curves for control and ibrutinib-
treated Zmpste24−/− mice. All treated mice in this figure were given 10 mg/kg ibrutinib. The median lifespan of control and treated mice did 
not differ significantly (p = .2813) by the log-rank (Mantel–Cox) test. However, survival in the boxed area, corresponding to the longest lived 
mice (top third of each cohort), showed a statistically significant difference (p = .0144). n = 18 (control) and 20 (ibrutinib). (b) Clinical Frailty 
Score in the same experiment. See Table S2 for parameters used. Each parameter is scored as absent (0), mild (0.5) or severe (1), and the total 
sum of values for each mouse is recorded. n = 18 (vehicle) and 20 (ibrutinib). Data are presented as the mean of the values, and statistical 
analysis of the boxed area is done using an unpaired t test. *p = .0248. (c) Late life clinical frailty scores of the boxed area in (b), presented in a 
box and whiskers plot showing median (bar), upper and lower quartiles (box) and lowest and highest values (error bars). Each dot represents 
one mouse. *p = .0248
F I G U R E  2   BTK expression is increased in aged mouse brains. (a) Representative images of immunohistochemical staining of wild-type 
young (3 weeks) and old (70 weeks) mice brains using a BTK antibody and an isotype control. (b) Quantitation (percentage of DAB) of 
samples in (a), taken from three mice per group (six pictures taken from each animal). Bars show average values, and error bars represent 
standard deviation. (c) Representative Western blot of whole brain lysates from the same mice, showing the levels of expression of BTK and 
β-actin (loading control)
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in ameliorating age-related symptoms would likely vary between 
different organs. In an initial screen of different normal mouse tis-
sues (Figure S1c), we observed that BTK expression increased sub-
stantially in different organs of old wild-type mice, including brain 
(Figure 2a,b). This was concomitant with the expression of p16, a 
known marker of senescent cells (Baker et al., 2011). Also, the av-
erage BTK protein expression in the aged brain was also increased 
when compared to young counterparts, as measured by Western 
blot (Figure 2c). This indicates that mouse brains significantly upreg-
ulate BTK expression over time and suggests that this tissue could 
be particularly sensitive to the BTK inhibitors in the context of aging.
2.3 | Reduction in senescent cells in the brain of 
progeroid mice after BTK inhibition
To test whether BTK inhibition could prevent the age-dependent 
buildup of senescent cells in the brain, we measured the expression 
of different markers of senescence in brains of control and ibruti-
nib-treated Zmpste24−/− mice. Immunostaining confirmed that BTK 
expression was reduced in treated mice, consistent with previous 
observations (Althubiti et al., 2016; Rada et al., 2017, 2018a). This 
was concomitant with a decrease in p53 and p16 levels, as expected 
(Figure 3a). In line with this, mRNA levels of BTK (which is a tran-
scriptional target of p53 (Althubiti et al., 2016)) and other markers 
of senescence were also decreased in the brain samples (Figure 3b). 
p53 mRNA levels did not change significantly, which is compatible 
with the post-translational effects of BTK on p53 levels (Althubiti 
et al., 2016). The reduction in senescent cell accumulation in brains 
of treated mice was confirmed by a whole organ SA-β-gal staining 
(Figure 3c). Interestingly, there was no change in the percentage 
of neurons with telomere-associated DNA damage response foci 
(TAF; Figure 3d) or histone γH2A.X foci (Figure 3e), both of which 
are markers of DNA damage that accumulate with age (Jurk et al., 
2014). This suggests that BTK inhibitors may prevent the onset of 
senescence despite the presence of the persistent high levels of 
DNA damage normally observed in aging and, particularly, in the 
Zmpste24−/− mouse model (Varela et al., 2005). These data together 
show that BTK suppression correlates with a decrease in senes-
cent cell accumulation in the brain of progeroid mice and suggests 
that the chemical inhibitors could have a potential effect on brain 
functions.
2.4 | Effect of BTK inhibitors on anxiety-
like behaviour
To determine the impact that BTK inhibition may have on brain 
functions during aging, we performed a series of tests on the ibruti-
nib-treated Zmpste24−/− mice. We first used the elevated plus maze 
(EPM) to measure anxiety-like behaviour in mice (Figure 4a), since 
anxiety has been shown to be strongly associated with aging (Perna, 
Iannone, Alciati, & Caldirola, 2016) and the presence of senescent 
cells (Ogrodnik et al., 2019). In the EPM test, we measured the will-
ingness of mice to explore the open arm of the maze, which is in-
versely proportional to the anxiety experienced (Loxton & Canales, 
2017; Walf & Frye, 2007), by counting the number of times a mouse 
entered into, and the time spent in, the open arms. As shown in 
Figure 4b, the entries and time spent in open arms were similar in 
all Zmpste24−/− mice before starting the ibrutinib treatment (basal). 
However, 12 weeks into the treatment (by then mice were 6 month 
old, close to the end of their lifespan), control mice did not venture 
into the open arms, while the mice receiving ibrutinib still explored 
them. Of note, treated mice explored less than what wild-type mice 
of similar age would do, which confirms the accelerated aging of 
the Zmpste24−/− mice. These results suggest that BTK inhibition was 
able to reduce anxiety-like behaviour in prematurely aged mice, 
consistent with an amelioration of age-related symptoms in a tissue 
with cells that would normally express high levels of BTK.
2.5 | BTK inhibition prevents age-dependent long-
term spatial memory loss
To further explore the impact of BTK inhibition in cognitive func-
tions of old mice, we next used the Barnes maze (Capilla-Gonzalez 
et al., 2012) to assess long-term spatial memory, since memory loss 
is also associated with aging (Esiri, 2007; Figure 5a). This experiment 
was chosen because it relies on extra-maze visual cues and does 
not use strong aversive stimuli, thereby inducing less stress in the 
F I G U R E  3   Ibrutinib reduces the accumulation of senescent cells in the aging brain. (a) Representative images of immunostaining 
of brain of control and 10 mg/kg ibrutinib-treated Zmpste24−/− mice, 121 days after the beginning of treatment (196 days old), using 
antibodies against BTK and other known markers of senescence (p53, p21, p16), compared with an isotype control. Magnification: 40×. 
Graph shows quantitation of 8–15 animals per group (and 1–6 pictures taken from each animal). Lines show mean values of the percentage 
of DAB, and error bars show standard deviation. Each dot represents one sample. *p < .03; **p < .003; ***p < .0003 (unpaired t tests). (b) 
mRNA expression levels of different senescent markers as measured by quantitative real-time PCR of samples from the ibrutinib-treated 
Zmpste24−/− mice, normalized to the expression of the same genes in control mice (represented by the blue bar). Included are BTK and p53, 
as well as SASP markers (IL-1B and IL-6) and markers previously described by us (PLD3, VPS26A and ARMCX3). All values were previously 
normalized to GAPDH expression. n = 4–7. All experiments were done in triplicates. Bars represent mean values, and error bars represent 
standard deviation. ****p < .0001; ***p = .0002; ns: not significant (unpaired t tests). (c) Representative SA-β-gal staining of fragments of the 
brains of two control and two 10 mg/kg ibrutinib-treated Zmpste24−/− mice 70 days after the beginning of treatment. (d) Mean number of 
telomere-associated foci in CA3 neurons of the hippocampus of control and 10 mg/kg ibrutinib-treated Zmpste24−/− mice 121 days after the 
beginning of treatment. Bars represent average values, and error bars represent standard deviation. n = 5. (e) Mean number of γH2A.X foci 
in the CA3 neurons of the same mice
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animals than other mazes used for cognitive assessment, such as 
the radial arm maze and the water mazes (Loxton & Canales, 2017). 
During the acquisition phase, mice were trained for a week to find 
a hole that lead to an escape box in a circular surface, which had 
19 other holes with no boxes. Control and treated premature aging 
mice showed similar acquisition curves, also comparable to those of 
wild-type mice, which indicates that the Zmpste24−/− mice had no 
learning impairment (Figure 5b and S2). However, when the experi-
ment was repeated 2 weeks later, mice treated with 20 mg/kg ibru-
tinib were significantly faster at recalling the location of the escape 
box (Figure 5c and Videos S1 and S2). These results together indi-
cate that ibrutinib can prevent the loss of different brain functions 
and link for the first time BTK expression with age-related organ 
decay.
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3  | DISCUSSION
Understanding the biological mechanisms implicated in organismal 
aging has been a long-standing priority, given the huge social and 
economic impact that any strategy to ameliorate it could potentially 
have. After decades of intensive research, the main processes that 
determine human aging have begun to be outlined (Lopez-Otin et 
al., 2013). This provides a blueprint to devise strategies to slow or 
delay the age-dependent functional decay of tissues and organs. 
Preventing the accumulation of senescent cells, one of the hallmarks 
of aging that is more amenable to manipulation, can be achieved 
mainly through two different routes: increasing the clearing of 
these cells or blocking their emergence. While we previously re-
ported tools that could be used for the former (Althubiti et al., 2014; 
Althubiti & Macip, 2017; Ekpenyong-Akiba et al., 2019), in this study 
we propose a way to influence the latter.
The pathways that lead to cellular senescence have been well 
studied, and they have been found to mostly converge on the p53-
p21 and the p16-Rb axes. Dampening the activity of either of them 
could thus result in a decreased induction of senescence and an 
eventual reduction in the number of senescent cells present in old 
tissues. Here, we show a pharmacological intervention, based on our 
previously published in vitro observations of its effect on the p53 
pathway (Althubiti et al., 2016; Rada et al., 2017), that has a signifi-
cant impact on lifespan and healthspan of mammals.
The obvious downside of this and similar approaches would 
be that the inhibition of essential tumour suppressor pathways, to 
which p53 contributes importantly, could increase tumourigenesis. 
Slowing down the age-related decline at the cost of increasing the 
probability of cancer development would be a moot point. However, 
the possibility that the anti-tumour and pro-aging functions of 
p53-induced senescence could be uncoupled has been intensively 
debated. Several mouse models were developed to address this 
question, with initial reports showing that excessive p53 activity 
would protect against cancer but lead to premature aging (Maier et 
al., 2004; Tyner et al., 2002). However, it was later demonstrated 
that an increased p53 load could actually prevent cancer without 
increasing aging if it were under the proper control mechanisms 
(Garcia-Cao et al., 2002). The converse experiment, eliminating p53 
to test whether this increases lifespan, has not been possible due to 
the fact that cancers inevitably arise early in knockout mice (Harvey 
et al., 1993). Here, we present the first demonstration that a reduc-
tion in p53 activity in mice ameliorates the aging-related impact on 
physiological cognitive/affective functions.
To establish the clinical relevance of BTK inhibition in senes-
cence, we chose the Zmpste24−/− progeroid mouse model for the 
convenience of a short lifespan, which allows faster and more ac-
cessible experiments. Although average lifespan was not increased 
in this model, we observed differences in parameters linked to 
healthspan, showing that BTK inhibition indeed had an impact on 
aging. Importantly, there was no increase in tumourigenesis in our 
experiments, which suggests that other tumour suppression mecha-
nisms were still capable of protecting these animals despite the im-
pairment in p53-induced senescence.
The fact that the effects on lifespan were moderate, despite a 
significant reduction in frailty, suggested that BTK inhibition had a 
heterogeneous impact in preserving organ function, probably linked 
to tissue-specific levels of BTK expression and the role of the p53 
pathway on the aging processes of each organ. We are currently per-
forming a detailed exploration of how BTK inhibitors may protect 
different tissues from aging, which will form the basis for future re-
ports. Here, we focused on the brain, which showed a high increase 
in BTK expression during aging.
Our results indicate that brain functions that are affected during 
the aging process may be preserved when BTK activity is blocked, 
which is consistent with the fact that ibrutinib has been shown 
to cross the blood–brain barrier (Bernard et al., 2015). This also 
shows an important role of p53 in the brain aging in this model. The 
F I G U R E  4   BTK inhibitors reduce anxiety-like behaviour in Zmpste24−/− mice. (a) The Elevated plus maze used to assess anxiety-like 
behaviour. (b) Average entries and time spent by wild-type, control and 10 mg/kg ibrutinib-treated Zmpste24−/− mice in the open arms of an 
Elevated plus maze, 12 weeks after the beginning of treatment. Error bars represent standard deviation. n = 10 for each group. No significant 
differences were observed in the basal measurements; p = .6 (time) and 0.2 (entries), as measured by one-way ANOVA. *p = .03; **p = .003 
(unpaired t tests)
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mechanism involved could be a reduction in the presence of senes-
cent cells in the old brain, as suggested by our biochemical analyses, 
which would be consistent with a recently published report showing 
that clearance of senescent glial cells prevents cognitive decline in 
mice (Bussian et al., 2018). However, other senescence-independent 
functions of BTK could also be playing a role. Thus, further studies 
will be needed to fully elucidate the mechanisms involved in the ef-
fects of BTK inhibitors on brain aging.
Of note, blocking p53 activation through BTK inhibition does not 
prevent the accumulation of damage in the neurons normally ob-
served in aging. This shows that although these triggers for senes-
cence are still present, lack of BTK prevents the cell for mounting 
a full senescent response. It also reinforces the hypothesis that it 
is not the cellular damage itself but the excessive presence of se-
nescent cells what disrupts tissue homeostasis and activity in aging.
Our study suggests that interfering with the p53 pathway by re-
moving BTK’s regulation could reduce certain features of the aging 
phenotype without increasing the risk of neoplasia. The fact that in-
hibition of p53 caused by blocking BTK is not complete (Althubiti et 
al., 2016) could explain why ibrutinib does not fully recapitulate the 
phenotype of a p53 null mouse. Other aspects of the impact of BTK 
inhibition on lifespan and healthspan should also be carefully con-
sidered. First, it will be important to reproduce these results in wild-
type mice to assess the role of BTK in normal organismal aging. A 
careful monitoring of the cancer load in these animals will be crucial 
to confirm that BTK inhibitors do not interfere with critical tumour 
suppressor functions. Of note, these drugs are currently being used 
in the clinic to treat leukaemia and, so far, long-term follow-up stud-
ies have not reported a significant increase in secondary tumours 
(Walter et al., 2017). It is possible that blocking p53-induced senes-
cence through BTK inhibition is not sufficient to disrupt the complex 
antineoplastic pathways of the cell. For instance, it has been recently 
proposed that there is an extensive functional overlap of different 
p53 functions in the context of tumour suppression, thus providing 
fail-safe mechanisms should any of them be deregulated individually 
(Janic et al., 2018). Also, the aging phenotype in normal mice may 
not be as dependent on the p53 pathway as in Zmpste24−/− mice, and 
thus, the effects of BTK inhibitors could be less intense.
It is important to consider that the absence of other regulatory 
kinases upstream of the p53 pathway has been shown to be embry-
onically lethal, such as is the case of ATM (Daniel et al., 2012) and 
ATR (Brown & Baltimore, 2000). However, mice lacking BTK develop 
normally, although they are severely immunocompromised due to 
the role of BTK in early B-cell development (Kerner et al., 1995; Khan 
et al., 1995). These more limited side effects make BTK a unique 
target to study the role of the p53 pathway in aging. A conditional 
knockout model that could switch off BTK at later stages in life could 
be useful to quantify its impact on aging, since the strong effect that 
the absence of BTK has on the immune system during development 
could mask any potential increase in healthspan or lifespan.
It would also be necessary to establish a range of doses of inhib-
itors that have an effect on different aspects of aging, beyond the 
ones that we used, which were based on information available for 
the antileukemic effects of ibrutinib (25 mg/kg is a concentration 
often used in vivo [Reiff et al., 2018]). Like most targeted inhibitors, 
ibrutinib is not totally specific and also blocks other kinases. Thus, 
it cannot be ruled out that some of these off-target effects contrib-
ute to the outcomes we observed. Other BTK inhibitors with higher 
specificity should be tested in mice to determine whether the effect 
F I G U R E  5   BTK inhibition ameliorates the age-dependent 
decline of spatial memory. (a) The Barnes maze set-up used for 
cognitive function tests. The target hole is indicated by the red 
arrow in the figure and fixed visual cues on the wall are indicated 
by black arrows. A camera positioned on the ceiling recorded the 
experiments. (b) Percentage of nose pokes that were made on the 
target hole by mice during the acquisition period of the Barnes 
maze test, which reflects the ability to learn the task. Control and 
10 mg/kg ibrutinib-treated Zmpste24−/− mice were compared to 
wild-type mice. There were no statistical differences between the 
three groups in any of the 3 days recorded. n = 13 (control) and 15 
(ibrutinib). (c) The box and whiskers plot show the recall latency 
for control and 20 mg/kg ibrutinib-treated Zmpste24−/− mice in 
Barnes maze trials performed 14 days after acquisition, 14 weeks 
after the beginning of treatment (24 weeks of age). n = 6 (control) 
and 5 (ibrutinib). Statistical significance was determined using the 
unpaired t test. *p = .01
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is maintained. Finally, it would be interesting to determine whether 
interrupting senescence with BTK inhibition has any effect on lifes-
pan and healthspan if done at later stages of life. In our experiments, 
these drugs were given to mice continuously from around the begin-
ning of the second third of their lives, what could be the equivalent 
of the fourth decade in humans. For them to be used to ameliorate 
aging in humans, it would be convenient if they could be adminis-
tered following intermittent patterns and/or the treatment could 
get started at later stages, closer to the last third of life, where the 
symptoms of aging and loss of brain functions start becoming more 
evident.
In summary, we have presented evidence that BTK inhibition can 
have a positive impact on mammalian healthspan in the absence of 
increased carcinogenesis and that the chemical inhibition of an up-
stream kinase of the p53 pathway using already clinically approved 
and well-tolerated drugs results in an amelioration of the age-related 
functional decline in fast-aging mice. This should accelerate any po-
tential translational applications. An immediate one could be the re-
purposing of ibrutinib (and other BTK inhibitors currently in clinical 
trials) to treat progeroid syndromes. Eventually, they may be shown 
to be useful to prevent senescent cell accumulation in certain situ-
ations, such as Alzheimer's disease, as well as reducing the frailty 
associated with normal aging. However, further experiments will be 
needed to fully understand the role of BTK in aging and its therapeu-
tic relevance in senescence-related diseases.
4  | E XPERIMENTAL PROCEDURES
4.1 | Senescence-associated-β-galactosidase (SA-β-
Gal) staining
Freshly	 extracted	 brains	 were	 stored	 in	 −80°C	 until	 the	 time	 of	
the experiment. After defrosting, tissues were washed two times 
with 1× PBS and fixed with 10% neutral-buffered formalin at room 
temperature for 15 min. After fixation, the washes in 1× PBS were 
repeated two times and the 2–3 ml of staining solution (1 mg/ml 
X-gal in dimethylformamide [DMF], 40 mM citric acid/Na phosphate 
buffer pH = 6.0, 5 mM potassium ferrocyanide, 5 mM potassium fer-
ricyanide, 150 mM sodium chloride, 2 mM magnesium chloride in 
distilled	water)	was	added.	Samples	were	incubated	at	37°C	in	a	non-
CO2 incubator, and the blue-coloured β-galactosidase staining was 
observed after 24 hr of incubation.
4.2 | Immunoblot analysis
Brain from humanely culled study animals was cut into small pieces 
and mashed through a 40-µm cell strainer (Corning) using the piston 
of a syringe plunger (Terumo). The tissue homogenate was rinsed 
out	 using	 FBS	 with	 10%	 DMSO	 and	 stored	 at	 −80°C	 for	 future	
use. To extract protein from frozen tissue homogenates, 300 µl 
was taken from each cryovial and washed twice with PBS. Pellets 
were re-suspended in RIPA buffer. Samples were incubated on 
ice for 30 min, after which they were thoroughly lysed by passing 
through a syringe and 0.8 × 40 mm needle at least 20 times. 1 μg/
ml protease inhibitor cocktail set III (Calbiochem) was added to all 
cell lysates. Protein concentrations were determined using Bradford 
protein assay (Fermentas). 10–20 µg of total protein per sample was 
subjected to 10% or 6% SDS PAGE and transferred to immobilon-P 
membranes (Millipore) for Western blotting as previously described 
(Carrera et al., 2014). For antibodies used in Western blots, see Table 
S3. An ECL detection system (Thermo Scientific) was used to visual-
ize the results. For Ponceau staining, 1× Ponceau staining (Sigma, P 
3504) was added to the membrane for 5 min with shaking.
4.3 | Mouse model of premature aging
In vivo studies were carried out using the zinc metalloproteinase 
STE24 (ZMPSTE24) deficient mouse model of progeria, which has 
an average lifespan of 6–8 months (Pendas et al., 2002; Varela et 
al., 2005). Cryopreserved spermatozoa were purchased from 
the Mutant Mouse Resource & Research Centre at University of 
California, Davis, which is supported by the National Institutes of 
Health (NIH). The Zmpste24−/− sperm was implanted into recipient 
female wild-type C57BL/6J mice. Heterozygous offspring of the 
founder lines were further bred to create genetically altered strains 
deficient in the Zmpste24 gene. All research done using animals were 
conducted in adherence to the UK Home Office Animals (Scientific 
Procedures) Act 1986. For humane reasons, animals were allowed 
to be kept for a maximum of 8 months of age or when a humane 
end point was reached (see Table S1). All experiments were started 
when animals reached 2 months of age. Zmpste24−/− mice received 
either ibrutinib (dissolved in DMSO) or water with DMSO (controls). 
Animals from the same group were paired in cages, matched by sex 
and age. No two animals from the same experimental group were 
placed into the same cage. Animals were administered either 10 mg 
or 20 mg of Ibrutinib (PCI-32765, Selleck) per kilogram body weight, 
twice weekly by oral gavage, using a 1 ml syringe (Terumo) and a 
20 ga × 38 mm plastic feeding tube (Instech Laboratories).
4.4 | Mouse frailty scoring
A frailty assessment form based on several relevant clinical param-
eters (Whitehead et al., 2014) was used to score the frailty of the 
mice after physical examination (performed at least twice weekly). 
Hearing loss was assessed using a clicker pen; forelimb grip strength 
was assessed by placing the mouse on its cage grid and gently tug-
ging at its tail; vision was assessed by lifting the mouse and placing 
them down on the palm of the hand, fore limbs first, to see whether 
they could put down their paws to support themselves. Parameters 
were assessed and rated based on the severity as absent, mild or 
severe. The results were analysed on Microsoft Excel and GraphPad 
Prism 7.0.
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4.5 | Measurement of anxiety-like behaviours
A 4-armed EPM was used to measure anxiety-like behaviours in 
mice, as previously described (Lister, 1987; Loxton & Canales, 2017). 
Briefly, we constructed a maze of black Perspex, elevated 1 m above 
the floor, which consisted of two arms that were open and two other 
arms that were closed with black Perspex walls (Pellow, Chopin, File, 
& Briley, 1985). Mice were placed individually in the centre of the 
EPM and allowed 5 min to explore it. The mice's entries into open 
and closed arms and the time spent in each set of arms were re-
corded. The results were manually analysed by a blinded observer.
4.6 | Long-term spatial memory assessment
A Barnes maze was used to determine spatial memory in mice, as 
described (Barnes, 1979). Briefly, a white circular platform raised 1 m 
above the ground had 20 equidistant holes around its edges, with 
only one of them with a black escape box fitted underneath (tar-
get hole). White noise was played on speakers, while a mouse was 
placed in the centre of the platform under bright light. Visual cues 
and the position of the target hole were kept constant throughout 
the study. Acquisition (training) was carried for 5 days after an initial 
habituation session. Fourteen days after acquisition, the experiment 
was repeated with the escape box removed the hole sealed like all 
the others. The latency (time to locate the target hole) and number 
of nose pokes into the target hole (compared to those into the wrong 
holes) were calculated. Two blinded observers manually analysed 
the data obtained.
4.7 | Immunostaining
Brains were isolated from mice that were culled humanely and 
immediately placed into specimen collection tubes (Sterlin, No. 
25052B) containing 10% neutral-buffered formalin (Sigma-Aldrich) 
and fixed for 24–48 hr. Tissues were removed from formalin and 
placed in 70% ethanol before being processed into paraffin-embed-
ded tissue blocks. Formalin-fixed paraffin-embedded (FFPE) tissues 
were cut into 5-µm sections using a microtome (LEICA RM2235). 
Sections	 were	 then	 placed	 on	 a	 34°C	 tissue	 floatation	 bath	 (RA	
Lamb) to straighten out before being mounted on slides. Slides were 
previously coated with a solution of 3-aminopropyltriethoxysilane, 
as described (Maddox & Jenkins, 1987), to enhance tissue adhe-
sion. Slides were either air-dried overnight or dried in the oven at 
37°C	for	1	hr	and	then	dewaxed	in	two	changes	in	xylene	for	10	min	
each. They were then dehydrated in two changes of 100% ethanol 
for 10 min each, after which the slides were soaked in 400 ml of 
methanol containing 2.4 ml of 30% hydrogen peroxide for 10 min, to 
block endogenous peroxidase. Slides were thereafter microwaved 
for 15 min in citrate buffer in a pressure cooker for heat-mediated 
antigen retrieval and then washed with 1× PBS. The edges of the 
slides were dried, and a pap pen was used to mark around the tissue. 
Slides were incubated with 100 µl of 5% serum for 1 hr, after which 
the serum was drained, and slides were then incubated with primary 
antibody	overnight	at	4°C.	The	slides	were	washed	in	PBS,	and	the	
edges dried before incubating for 30 min with streptavidin-peroxi-
dase.	They	were	again	washed	and	incubated	with	DAB	(3,3′-diam-
inobenzidine) substrate and peroxidase for 5 min maximum. Slides 
were washed then dehydrated in 70%, 90% and 100% ethanol for 
10 min each. For antibodies used, see Table S3. Quantification (in-
tensity of staining expressed as the percentage of DAB signal in a 
field) was done using immunoratio (http://153.1.200.58:8080/
immun orati o/).
4.8 | Immunostaining and telomere-associated foci 
(TAF) and quantification
Paraffin sections were deparaffinized with histoclear and hydrated 
in an ethanol gradient followed by water and PBS. Antigen was 
retrieved	by	 incubation	 in	0.01	M	citrate	buffer	 (pH	6.0)	at	100°C	
for 10 min. Slides were placed in blocking buffer (1:60 normal goat 
serum [S-1000, Vector Laboratories] in 0.1% BSA/PBS) for 60 min 
at room temperature. For TAF staining, slides were additionally 
blocked with avidin/biotin (Vector Lab, #SP-2001) for 15 min each. 
Primary antibodies used (γH2A.X, table below) were diluted 1:250 
in	blocking	buffer	and	applied	overnight	at	4°C.	The	next	day,	slides	
were washed three times with PBS and incubated for 30 min with 
secondary goat, anti-rabbit antibody (1:200; Vector Laboratories 
#BA-1000). Fluorescein–avidin in PBS (1:500; #A-2011, Vector Lab) 
was applied to each sample for 20 min. Slides were washed three 
times in PBS, which was followed by FISH for TAF detection. Briefly, 
tissues were crosslinked with 4% paraformaldehyde for 20 min and 
dehydrated in graded ethanol. Sections were denatured for 10 min at 
80°C	in	hybridization	buffer	(70%	formamide	(Sigma),	25	mM	MgCl2, 
0.1 M Tris (pH 7.2) and 5% blocking reagent [Roche]) containing 
2.5 μg/ml Cy-3-labelled telomere-specific (CCCTAA) peptide nucleic 
acid probe (Panagene), followed by hybridization for 2 hr at room 
temperature in the dark. Slides were washed twice with 70% forma-
mide in 2× SSC for 15 min, followed by washes in 2× SSC and PBS 
for 10 min. Sections were mounted in Vectashield DAPI-containing 
mounting media and imaged. Anti-γ-H2A.X rabbit monoclonal anti-
body: Cell Signaling Technology # 9718; RRID: AB_2118009.
4.9 | Quantitative real-time PCR
Total RNA was extracted from FFPE mouse brain tissues using the 
ReliaPrep™ FFPE Total RNA Miniprep System Kit (Promega) and fol-
lowing manufacturers’ instructions. The concentration of RNA was 
measured using a NanoPhotometer P300 (Implen). Samples were 
used for cDNA synthesis using the Superscript™ III First-Strand 
Synthesis System for RT-PCR (Invitrogen), following manufactur-
er's instructions. Quantitative real-time PCR was performed in a 
LightCycler® 480 Multiwell Plate 96 (Roche) using SensiMix SYBR 
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No-Rox (Bioline), in triplicates, as previously described (Althubiti et 
al., 2016). For the primers used, see Table S4. All primers were sup-
plied by Eurofins Scientific. A melting curve was used to prove the 
specificity of the primers at the end of the PCR run. Quantification 
was	done	with	the	∆∆Ct method. Results were analysed on Microsoft 
Excel, and graphs plotted using GraphPad Prism 7.0 Software.
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